Pityriasis Rubra Pilaris (PRP)

🧠 Standard of Care & Symptoms

Pityriasis Rubra Pilaris (PRP) is a rare, chronic inflammatory papulosquamous disorder characterized by keratinization anomalies, follicular plugging, and waxy keratoderma.

• Presentation: Key cutaneous features.
  • Follicular Keratotic Papules: Small, firm, red-brown papules centered on hair follicles. They characteristically appear on the dorsal aspects of the fingers (giving a "nutmeg-grater" texture when stroked) and the limbs.
  • Orange-Red Scaling Plaques: Plaques expand and merge to cover large areas. Crucially, they exhibit **"islands of sparing"**—distinct, sharp patches of completely normal skin within the red, inflamed plaques.
  • Waxy Palmoplantar Keratoderma: Thick, yellow-orange, waxy scaling of the palms of the hands and soles of the feet, which can develop painful cracks (fissures).
  • Erythroderma: Progressive cases can lead to generalized red skin over the entire body, causing complications like hypothermia and high-output Heart Failure due to heat loss.

🧬 Diagnostics & CARD14 NF-κB Pathology

Diagnosis is established clinically based on presentation (follicular papules and islands of sparing) and confirmed via histopathology of a punch biopsy.

• Skin Biopsy: Histology shows characteristic signs.
  • Checkerboard Parakeratosis: Alternating vertical and horizontal layers of orthokeratosis (normal dead skin cells) and parakeratosis (dead cells with nuclei), producing a checkerboard pattern.
  • Follicular Plugging: Dilated hair follicles filled with keratin plugs, surrounded by parakeratotic cells.
  • Infiltrate: A mild perivascular lymphocytic infiltrate in the dermis.
• Genetic Testing: Confirms mutations in the **CARD14** gene in familial (Type V) and some atypical cases.

Pathogenesis & CARD14-Driven NF-κB Hyperactivation

The abnormal cell growth and epidermal inflammation in PRP are caused by a hyperactive scaffold protein inside skin cells:

• CARD14 Gene: Located on chromosome 17q25.3, it encodes **CARD14** (caspase recruitment domain-containing protein 14), a scaffold protein expressed primarily in epidermal keratinocytes.
• Constitutive NF-κB Activation: Pathogenic mutations in CARD14 disrupt its auto-inhibitory domain. This causes the protein to undergo spontaneous oligomerization and continuously activate the **NF-κB** transcription factor.
• Th17/IL-23 Cytokine Cascade: Active NF-κB drives massive transcription of inflammatory chemokines and cytokines, particularly **IL-23** and **IL-36**. This recruits Th17 cells, creating an inflammatory loop of **IL-17A** and **IL-22** that causes rapid keratinocyte hyperproliferation and checkerboard parakeratosis.

💊 Retinoids & Th17/IL-23 Biologics

Treatment combines systemic retinoids to normalize skin cell turnover with targeted Th17/IL-23 pathway biologics to halt inflammation.

Systemic Retinoids

• Acitretin (oral): The gold-standard first-line therapy. Acitretin binds to nuclear retinoic acid receptors to normalize keratinocyte differentiation, reduce follicular plugging, and thin waxy keratodermas.

Targeted Biologics

• Ustekinumab (anti-IL-12/23): Blocks the common p40 subunit of IL-12 and IL-23, preventing Th17 activation. Ustekinumab has demonstrated high clearance rates in refractory PRP cases.
• Secukinumab or Ixekizumab (anti-IL-17A): Directly blocks IL-17A, halting the Th17 inflammatory loop in patients who fail oral retinoids.
• Topical Care: Thick bland emollients and low-potency topical steroids are used as adjuncts. Avoid harsh exfoliants on raw plaques.

🔬 Active Clinical Trials

Clinical trials are currently evaluating selective IL-23 inhibitors like Guselkumab, oral CARD14 inhibitors, and digital palmoplantar tracking systems.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Pityriasis Rubra Pilaris, establish these care pathways:

1. Confirm Histopathology: Verify your skin biopsy shows "checkerboard parakeratosis" and follicular plugging to support the diagnosis of PRP over psoriasis.
2. Discuss Systemic Retinoids (Acitretin): Review dosing options with your dermatologist; this is the primary drug to normalize skin turnover.
3. Evaluate Biologic Therapies (Ustekinumab): If oral retinoids fail or cause severe dryness, discuss switching to Ustekinumab or Secukinumab.
4. Apply Thick Emollients to Palms and Soles: Use thick petrolatum ointments under occlusion (plastic wraps or cotton socks) overnight to heal waxy fissures.

❓ Patient FAQ

Q: What are "islands of sparing" in PRP?
A: "Islands of sparing" are a highly characteristic clinical feature of Pityriasis Rubra Pilaris (PRP). When the red, scaly skin plaques expand and merge across the body, they do not cover it completely. Instead, they leave behind distinct, sharp patches of completely normal-looking, healthy skin within the middle of the red, inflamed plaques. Finding these "islands" helps dermatologists differentiate PRP from psoriasis and eczema.

Q: How does PRP differ from psoriasis?
A: While both are scaly, red skin conditions, they differ in several ways. Psoriasis plaques are typically a bright silvery-white and concentrated on the elbows and knees. PRP plaques are a reddish-orange color, feel like a nutmeg-grater due to keratin plugs in the hair follicles, and have "islands of sparing." Furthermore, the palms of the hands and soles of the feet in PRP develop a very thick, waxy, yellow coating (keratoderma), which is less common in psoriasis.